Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines [Yahoo! Finance]
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Yahoo! Finance
that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a "Level 1B" evidence rating in the 2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) as a prognostic tool for the risk stratification of patients with localized prostate cancer. Level 1B was assigned to Decipher Prostate based on the evidence in both the post-biopsy and post-prostatectomy settings. Additionally, because of this classification, the Decipher Prostate test is the only gene expression test for which the guidelines synthesize the available published data in a separate table that summarizes treatment implications for patients based on both their NCCN risk classification and Decipher score. "We commend the NCCN panel for their evidence synthesis and expert consensus that has again designated the Decipher Prostate test as the gene expression tool for risk stratification supported by the most clinical evidence across the spectrum of the disease and has uniquely pr
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN [Yahoo! Finance]Yahoo! Finance
- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024Business Wire
- New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance [Yahoo! Finance]Yahoo! Finance
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceBusiness Wire
- CareDx appoints John Hanna as president and CEO [Seeking Alpha]Seeking Alpha
VCYT
Earnings
- 2/22/24 - Miss
VCYT
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- VCYT's page on the SEC website